 The purpose of this phase 2, multiple-cohort, randomized, open-label, international study of talazoparib a poly ADP-ribose polymerase PARP inhibitor is to compare the efficacy and safety of talazoparib monotherapy and talazoparib plus temozolomide in women with relapsed ovarian, fallopian tube, and peritoneal cancer. 